GLENMARK
Glenmark Pharmaceuticals Limited
Healthcare
Share price
₹2,311
Market cap
₹64,600 Cr
1Y return
▲ 17%
A global research-led pharmaceutical company, Glenmark operates across generics, specialty, and over-the-counter business segments with a presence in more than 80 countries worldwide. The company develops and manufactures pharmaceutical products serving patients across multiple therapeutic areas including oncology, dermatology, and respiratory care. Its distinctive strength lies in combining generic drug manufacturing capabilities with specialty pharmaceutical development and maintaining a robust international distribution network across developed and emerging markets.
Investors holding Glenmark Pharmaceuticals Limited
Recent moves 5
Bandhan Mutual FundExited
Bandhan Mutual Fund has dropped from Glenmark Pharmaceuticals Limited's disclosed shareholder list after previously holding a 1.17 percent stake, indicating either a complete exit or a reduction below the 1 percent disclosure threshold.
Read more
Government Pension Fund Global (Norway)Increased
Government Pension Fund Global (Norway) increased its stake in Glenmark Pharmaceuticals Limited from 3.78% to 3.89%, raising its shareholding from 10,674,228 to 10,985,826 shares. This change is worth ₹73.91 crore based on the current share price of ₹2301.30.
Read more
UTI Mutual FundDecreased
UTI Mutual Fund decreased its stake in Glenmark Pharmaceuticals from 1.27% to 1.15%, selling 3,19,539 shares worth ₹71.55 crore at ₹2235.50 apiece.
Read more
Invesco Mutual FundIncreased
Invesco Mutual Fund increased its stake in Glenmark Pharmaceuticals from 1.88% to 2.20%, purchasing 903,000 shares for ₹202.04 crore at ₹2235.50 apiece.
Read more
HDFC Mutual FundNew position
HDFC Mutual Fund entered Glenmark Pharmaceuticals with 1,75,66,947 shares, a 6.22% stake worth ₹3,924.96 Cr. This move resulted in crossing the 5% disclosure threshold.
Read more
Track the whales in Glenmark Pharmaceuticals Limited
Get alerted the moment a top investor buys or sells.
Get started